Patent application number | Description | Published |
20080320228 | METHOD AND APPARATUS FOR EFFICIENT REPLACEMENT ALGORITHM FOR PRE-FETCHER ORIENTED DATA CACHE - Disclosed are a method and apparatus for replacing pre-fetched data in a pre-fetch cache. In one embodiment, each line of the pre-fetch cache will be accessed at most M times. A line accessed M times can be evicted from the cache without any performance loss. In this embodiment, a counter is added to each pre-fetch data line to track how many times it has been accessed. In another embodiment, a displacement bit is added to each pre-fetch data line, and when a defined portion of the data line is accessed, this bit is set to a given value, indicating that the line can be evicted. | 12-25-2008 |
20090049272 | METHOD FOR IMPROVING THE PERFORMANCE OF SOFTWARE-MANAGED TLB - Exemplary embodiments of the present invention comprise a method for the utilization of entry-replacement index hint information within a software-managed TLB. The method comprises receiving an address translation request at a TLB and retrieving the address translation information from a page table in the event of a miss lookup event at the TLB. The method further comprises retrieving index replacement hint information from a hardware component, wherein the hardware component is configured to execute a predetermined replacement algorithm and writing the address translation information to a TLB index referenced within the index replacement hint information. | 02-19-2009 |
20150178089 | LOAD SYNCHRONIZATION WITH STREAMING THREAD COHORTS - There is provided a processor implemented method for controlling a lock-stepped cohort. The method includes receiving instructions for each of a first lane and a second lane. The first lane is for the lock-stepped cohort and the second lane is for another cohort. The method further includes detecting a condition in which a first instruction at the first lane will have a higher latency than a second instruction at the second lane. The method also includes setting an indicator indicating where the first lane encountered the first instruction. The method additionally includes setting the first lane to inactive, while keeping the second lane active. The method further includes setting the first lane to active on a subsequent opportunity to execute said first instruction. | 06-25-2015 |
Patent application number | Description | Published |
20100143363 | CD161 LIGAND, PILAR, FOR MODULATING ACTIVATION AND PROLIFERATION OF T CELLS - The invention relates to a CD161 ligand known as Proliferation-Induced Lymphocyte-Associated Receptor (PILAR), which is crucial for a robust expansion of human lymphocytes. PILAR is markedly up-regulated on both CD4 and CD8 T cells upon TCR engagement and increases the expression of anti-apoptotic genes and glucose transporters through CD161, which globally results in a dramatic enhancement of T cell proliferation. Agents which stimulate or block this activity are also provided as are methods for manipulating PILAR signaling in the treatment of disease. | 06-10-2010 |
20110098558 | SYSTEM AND METHOD FOR USE OF NANOPARTICLES IN IMAGING AND DIAGNOSIS - A method for diagnosing certain types of cancers provides a nanoparticle agent to be uptaken by cancer cells for diagnosis and treatment of certain cancers. A compound containing nanoparticles is directed toward a tumor site, and then a predetermined time period passes to allow the nanoparticles to be uptaken by the cancer cells. Imaging is then performed on the nanoparticles by an appropriate imaging device to determine the concentration of nanoparticles uptaken by the cancer cells. Finally, image data provided by the imaging device is analyzed to determine the concentration of nanoparticles and thereby determine whether a tumor is present. The nanoparticle agent can further be employed as a treatment of certain cancers. After the uptake of nanoparticles into the cells, a predetermined field applied to the nanoparticles for a sufficient period of time activates the magnetic cores of the nanoparticles to include hyperthermia-mediated destruction of the cancer cells. | 04-28-2011 |
20120039985 | DENDRITIC CELL MODULATION IN POST-ISCHEMIC WOUNDS - Compositions and methods useful for targeted depletion or modulation of dendritic cells are provided. The compositions and methods can be used to promote healing of ischemia-related injury, including ischemia-reperfusion injury. Disclosed are a variety of dendritic cell-targeted toxins, bone morphogenetic protein 7 (BMP7) agonists, and dendritic cell-targeted transforming growth factor beta 1 (TGF-β1) antagonists, all useful in practicing methods of the invention. The inventive compositions and methods can be used in the treatment of various conditions including myocardial infarction, stroke, and critical limb ischemia. | 02-16-2012 |
Patent application number | Description | Published |
20090274688 | Antibodies to OPGL - Antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are described. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are described. | 11-05-2009 |
20100255538 | ANTIBODIES TO INSULIN-LIKE GROWTH FACTOR I RECEPTOR - The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), which is preferably human IGF-IR. The invention also relates to human anti-IGF-IR antibodies, including chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulin molecules derived from anti-IGF-IR antibodies and nucleic acid molecules encoding such molecules. The present invention also relates to methods of making anti-IGF-IR antibodies, pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-IGF-IR antibodies. The invention also relates to gene therapy methods and transgenic animals comprising nucleic acid molecules of the present invention. | 10-07-2010 |
20120005767 | ANTIBODIES TO INSULIN-LIKE GROWTH FACTOR I RECEPTOR - The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), which is preferably human IGF-IR. The invention also relates to human anti-IGF-IR antibodies, including chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulin molecules derived from anti-IGF-IR antibodies and nucleic acid molecules encoding such molecules. The present invention also relates to methods of making anti-IGF-IR antibodies, pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-IGF-IR antibodies. The invention also relates to gene therapy methods and transgenic animals comprising nucleic acid molecules of the present invention. | 01-05-2012 |
20120087923 | Antibodies to OPGL - Antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are described. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are described. | 04-12-2012 |
20140134157 | ANTIBODIES TO OPGL - Antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are described. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are described. | 05-15-2014 |
Patent application number | Description | Published |
20140111113 | SIMPLIFIED CURRENT SENSE FOR BUCK LED DRIVER - A current sense and feedback circuit is provided for a non-isolated Buck power converter to maintain constant current load regulation. The Buck converter may have a high side power switch and may include an input port, a switcher unit including a switch and a controller, an inductor coupled to the output, and a freewheeling diode for circulating the inductor current when the switch is open. The simplified current sense and feedback circuit of the power converter may include a current sense resistor module coupled to the freewheeling diode to provide a sense signal to the controller. The controller may also be coupled to the output of the power converter to sense an over voltage condition. The simplified current sense and feedback circuit may provide output regulation while maintaining a low component count, small size, and low loss that makes the power converter suitable for use in compact design applications. | 04-24-2014 |
20140265861 | CURRENT LIMITER WITH ACTIVE DAMPING - This relates to a current limiter circuit that can be used in a power conversion system having a triac dimmer. In one example, the power conversion system may be used in an off-line LED driver. The current limiter circuit may be coupled to a power converter of the power conversion system and may operate to reduce the current that the power converter receives from an input line in the event of a power line surge. The current limiter circuit may also be coupled to the triac dimmer and may also operate as a damper for a portion of the half line cycle. The current limiter circuit may dampen the ringing in the triac current for a portion of the half line cycle and may cease dampening for the remaining portion of the half line cycle. | 09-18-2014 |
20140265898 | LOSSLESS PRELOAD FOR LED DRIVER WITH EXTENDED DIMMING - A quasi-phase active preload circuit to be coupled at the output of a non-isolated LED driver converter having a pre-stage phase-angle control dimmer circuit, such as a commonly used leading-edge control Triac dimmer, is disclosed. The quasi-phase active preload circuit may include a preload resistor coupled to a current-controlled current source configured to draw a sinking current through the preload resistor based on a peak detect signal. The peak detect signal may be, in one example, representative of a leading-edge peak voltage of an output of the Triac dimmer circuit, which may be representative of a conduction angle of the Triac dimmer circuit. During normal operating conditions, no sinking current is drawn through the preload resistor. During low dimming conditions, a sinking current that is responsive to the peak detect signal is drawn through the preload resistor. During deep dimming or when used with a leaky Triac dimmer, a maximum sinking current may be drawn through the preload resistor by the current-controlled current source. | 09-18-2014 |